Decline in the AIDS and death rates in the EuroSIDA study: an observational study

@article{Mocroft2003DeclineIT,
  title={Decline in the AIDS and death rates in the EuroSIDA study: an observational study},
  author={Amanda Mocroft and Bruno Ledergerber and Christine Katlama and Ole Kirk and Peter Reiss and A d'Arminio Monforte and Brygida Knysz and Manfred Dietrich and Andrew N Phillips and J D Lundgren},
  journal={The Lancet},
  year={2003},
  volume={362},
  pages={22-29}
}
BACKGROUND Since the introduction of highly active antiretroviral therapy (HAART), little is known about whether changes in HIV-1 mortality and morbidity rates have been sustained. We aimed to assess possible changes in these rates across Europe. METHODS We analysed data for 9803 patients in 70 European HIV centres including ones in Israel and Argentina. Incidence rates of AIDS or death were calculated for overall and most recent CD4 count in 6-monthly periods and in three treatment eras (pre… 
Differential improvement in survival among patients with AIDS after the introduction of HAART
TLDR
Substantial improvements in survival after the introduction of HAART were found for all PWA but varied by specific ADIs and the degree of immunosuppression, and was marked during the late HAART period across all HIV transmission categories, including intravenous drug use.
Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990-2011
TLDR
Despite of significant improvement of survival, there was still a high risk of early death in patients presenting in HAART era, mainly due to late human immunodeficiency virus (HIV) diagnosis and late presentation to care.
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis
TLDR
Virological response after starting HAART improved over calendar years, but such improvement has not translated into a decrease in mortality.
Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study
TLDR
Although overall death rates remained low through 2004, the proportion of deaths attributable to non- AIDS diseases increased and prominently included hepatic, cardiovascular, and pulmonary diseases, as well as non-AIDS malignancies.
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
TLDR
Although the incidence of all AIDS-defining events decreased substantially after starting HAART, the pattern of decline was most pronounced for events with a viral etiology, suggesting that changes in these markers did not fully explain the changes in incidence seen.
Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study
TLDR
There are significant differences in the rate of all-cause mortality among HIV-positive individuals across different regions of Europe and Argentina and these findings are important for understanding and reviewing HIV treatment strategies and policies across the European region.
Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan.
TLDR
It is suggested that the survival of persons in the late stage of HIV infection in Taiwan continued to improve in the early-HAART era and in theLate HAART era.
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy
TLDR
A significant and progressive decrease in mortality and increase in life expectancy were observed over the 12-year study period and were directly associated with the use of modern forms of HAART.
HIV in Denmark and Greenland, 1995–2004, the effect of highly active antiretroviral therapy and characteristics of the HIV-infected population: an observational study
TLDR
The aims of this thesis were to examine temporal trends in deaths, new infections, and individual patients characteristics among the Danish HIV-infected population, and to estimate acquisition of antiretroviral drug-resistant virus over time.
Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort
TLDR
During the first four years, a uniform decline of ADI incidence was observed even in patients with low CD4-cell counts at HAART initiation as long as the viral load remained undetectable.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study
TLDR
The proportion of pre-AIDS deaths increased from 1994 to 2001; however, the incidence of pre -AIDS deaths and deaths overall declined; therefore, it is essential to continue to monitor all causes of mortality to identify changes.
Changing patterns of mortality across Europe in patients infected with HIV-1
TLDR
Death rates across Europe among patients infected with HIV-1 have been falling since September, 1995, and at the beginning of 1998 were less than a fifth of their previous level.
AIDS across Europe, 1994–98: the EuroSIDA study
TLDR
The findings lend support to the idea that treatment regimens can lower the incidence of ADIs, and the immediate risk of an ADI for a given CD4 lymphocyte count has declined over time and is lower among patients on HAART.
Changes in use of antiretroviral therapy in regions of Europe over time
TLDR
Use of antiretroviral therapy in Europe has changed dramatically towards combination treatment in the last few years, and regional differences in use of antifiltration therapy have decreased, and by September 1997 only minor differences remained.
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study
TLDR
The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality in Switzerland.
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group.
  • J. Lundgren, A. Phillips, +10 authors C. Pedersen
  • Medicine
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
  • 1997
TLDR
ARV therapy was more frequently used among patients from southern and central Europe as compared with patients from northern Europe, especially among patients with CD4 counts >200 cells/microl, and antifungal therapies are used differently in different parts of Europe.
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
TLDR
The CD4 cell count at initiation was the dominant prognostic factor in patients starting HAART, and should be taken into account in future treatment guidelines.
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
TLDR
The rate of virological failure of HAART was high among patients with a history of antiretroviral treatment, but the probability of clinical progression was low even in patients with viral rebound.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
TLDR
The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions
TLDR
The hypothesis was that the virologic response to HAART would be substantially worse among unselected patients in an inner-city clinic than among patients enrolled in clinical trials, and this study analyzed data from a cohort of protease inhibitor-naive patients in whom HAART was initiated in the clinic between March 1996 and February 1998.
...
1
2
3
...